Nitrates decrease pulse pressure more than mean arterial pressure (MAP) and are advocated for the treatment of isolated systolic hypertension (ISH). Nitrates show drug tolerance during chronic treatment so an asymmetric dosing regimen may prevent loss of effect of nitrates. This study investigates the anti-hypertensive effect of isosorbide dinitrate (ISDN) given in a twice daily asymmetric dosing regimen in elderly patients with ISH.
Introduction
Isolated systolic hypertension (ISH) is characterised by a disproportionate increase in systolic blood pressure (SBP) without an elevation of diastolic blood pressure (DBP). In general, ISH is defined by a SBP above 160 mm Hg and a DBP below 90-95 mm Hg. 1 Several studies have shown that SBP increases with age. 2, 3 As DBP decreases after 50 years of age, pulse pressure increases. It has been demonstrated that the prevalence of ISH increases with age from approximately 5% at 60 to 24% at 80 years. [3] [4] [5] Since the number of elderly people is still rising, ISH and its complications is becoming a major public health issue. Epidemiological studies have shown an increased risk of stroke and cardiovascular morbidity and mortality with ISH. 2, 4, [6] [7] [8] In addition, these studies have clearly demonstrated that SBP is an important and independent cardiovascular risk factor. 2, 6, 9 In patients with ISH mean arterial pressure (MAP) and vascular resistance may be normal or slightly elevated, while pulse pressure, the difference between SBP and DBP, is increased. [10] [11] [12] It has been shown that an increase in pulse pressure contributes considerably to the increase in cardiovascular morbidity and mortality seen at higher ages. 13 Pulse pressure, for a given stroke volume, is determined by the ejection rate of the left ventricle, the timing of reflected waves and the visco-elastic properties of the arterial wall, such as large artery compliance. [12] [13] [14] In elderly patients with ISH (Ͼ50 years of age) the increase in pulse pressure is mainly due to a direct decrease in large artery compliance and to an indirect lowering of arterial compliance by an increase in early pulse wave reflections.
The SHEP study and SYST-EUR have shown that patients with ISH benefit from treatment. 4, 8 Classical anti-hypertensive drugs decrease SBP as well as DBP. DBP determines coronary perfusion and thus influences an adequate oxygen supply to the heart. 15 A curvilinear (J-shaped curve) relation has been described for the extent of BP reduction through anti-hypertensive therapy and the occurrence of myocardial infarction. 16, 17 The J-curve was seen especially in elderly patients. 18 In ISH patients the coronary system will be frequently narrowed because of atherosclerosis, while left ventricular hypertrophy will impair metabolic supply in case of a large reduction in DBP. 19 Consequently, with the classical anti-hypertensive agents, a further decrease of DBP in patients with coronary artery disease and ISH could be harmful. 16, 18, 20 Low-dose nitrates result in a selective dilation of large arteries, leading to an increase in arterial compliance, while almost no effect on arteriolar tone is present. In addition, nitrates are able to reduce wave reflection. 3, 10 As a consequence, nitrates can decrease SBP without a change in DBP. 21 Therefore, nitrates have been advocated for the treatment of ISH. However, the development of drug tolerance may limit the effect and use of nitrates as a therapy for ISH. Using an eccentric dosing regimen, such as is used in patients with angina, this tolerance can be avoided. 22 The aim of the present study was to investigate whether nitrates, given in an eccentric dosing schedule, can be effective and safe for the treatment of elderly patients with ISH.
Subjects and methods

Study design
The study was designed as a multicentre, doubleblind, placebo-controlled, randomised, parallel study. After a 6-week placebo run-in period, patients were randomised. BP and heart rate measurements were performed at the recruitment visit, 3 weeks before randomisation and at randomisation. Patients were included on the basis of BP at randomisation. They were given placebo or isosorbide dinitrate (ISDN) for 8 weeks. The patients started with ISDN 20 mg b.i.d. or placebo. If, after 2 weeks, SBP remained above 160 mm Hg, the dose could be doubled once. To avoid drug tolerance, patients were asked to take the medication at 8 am and 2 pm. Before, after 2 weeks, and at the end of the 8-week treatment period, BP and heart rate measurements were performed.
The study was approved by the ethics committees of the different centres and was performed in accordance with the Declaration of Helsinki (revised version 1983).
Patients
Thirty-one ISH patients of either sex between 60 and 80 years of age were selected from the out-patient clinics. Demographic data were collected and patients were checked for exclusion criteria. In addition, a general physical examination and a routine laboratory screening were carried out. Informed consent was obtained from all patients.
Major exclusion criteria were a history of myocardial infarction, cardiac surgery or angioplasty within the last 3 months, unstable angina, severe anaemia, renal or hepatic disease, neurologic abnormalities, pulmonary or endocrine disease except non-insulin dependent diabetes mellitus (NIDDM), peripheral arterial disease or treatment with other drugs known to affect BP.
At randomisation, patients should have a sitting DBP lower than 95 mm Hg and a SBP between 160 and 200 mm Hg. Twenty-five patients were randomised, 14 were subsequently treated with ISDN and 11 with placebo. Laboratory values showed no clinically relevant abnormalities at randomisation in all patients. Demographic and haemodynamic parameters at randomisation are shown in Table 1 .
Measurements
Office measurements: All haemodynamic measurements were performed in a sitting position after at least 10 min of rest in a warm (22 ± 1°C) and quiet room. Measurements were repeated with at least a few minutes interval. The mean of three measurements was used as the average BP value. BP was measured between 10 and 12 am with a mercury sphygmomanometer on the patient's non-dominant arm. DBP was determined at Korotkoff's phase V. Pulse pressure (PP) was calculated as SBP-DBP. MAP was calculated as SBP + 1/3DBP. Heart rate was determined by counting radial pulsations for 30 sec.
Ambulatory BP monitoring (ABPM):
In a subset of centres a 24-h ABPM was performed using a Spacelabs 90207 monitor (Spacelabs Inc, Redmond, WA, USA). During the day (7 am to 11 pm) BP was recorded every 15 min, during the night (11 pm to 7 am) every 30 min. Patients were instructed to stop muscular activity and to keep their arms entirely quiet during the measurements.
Drug adherence: Patients were asked for their drug adherence at the end of the 8-week treatment period and the number of tablets was counted.
Data analysis
Protocol-correct analysis was performed on all patients who completed the study. In addition, an intention-to-treat analysis was performed on all ran- 
Results
Twenty-one patients completed the study, 11 treated with ISDN (nine patients 40 mg b.i.d.; two patients 20 mg b.i.d.) and 10 with placebo. Four patients dropped out of the study after randomisation. Three of four were treated with ISDN and stopped because of headache. One patient of the placebo group was withdrawn because of atrial fibrillation. Within the group of patients that completed the study, five experienced an adverse event, four in the ISDN group (two headache, one backpain and one nausea) and one in the placebo group (headache).
Data for the office measurements are shown in Table 2 . Pulse pressure was significantly more reduced in the ISDN group (17.9%) than in the placebo group (5%; P Ͻ 0.05). Compared to randomisation SBP and MAP decreased with ISDN (SBP 9.6%; MAP 5.4%) and placebo (SBP 6.1%; MAP 6.5%), but the changes were not statistically significant between the two groups. Office DBP tended to increase with ISDN compared to placebo. No changes were observed for heart rate.
Data for the ABPM measurements are shown in Table 3 (SBP and PP). This substudy was performed Significant reductions in BP were seen in the ISDN group after 8 weeks of treatment. Mean 24-h values of SBP decreased compared to baseline (7.5%; P Ͻ 0.01) as well as mean daytime (9.6%; P Ͻ 0.01) and mean night-time SBP (5.1%; P Ͻ 0.05). For pulse pressure the same pattern was found with a decrease in mean 24-h (10.7%; P Ͻ 0.01), mean daytime (12.1%; P Ͻ 0.05) and mean night-time (7.9%; P Ͻ 0.05) values after treatment with ISDN. The decrease in daytime PP tended to be larger than the decrease in night-time PP. DBP did not differ statistically from baseline. No statistically significant changes in any of the ABPM parameters could be demonstrated in the placebo group.
Discussion
In the present study nitrates were used as monotherapy for the treatment of ISH. Differences in BP between ISDN and placebo (vs randomisation) were comparable after 2 and 8 weeks of treatment. Therefore, with the eccentric dosage regimen no tolerance effects could be demonstrated within a treatment period of 8 weeks. Adverse effects were more pronounced in the ISDN group. Most of these patients complained about headache, which is a well-known adverse effect with nitrates. 23 Apart from the cut-off level for DBP (90 or 95 mm Hg), one of the most significant factors affecting prevalence of ISH is the number of occasions on which BP is measured. 24 With repeated measurements the prevalence of ISH decreases considerably. 6 It is therefore not surprising that in the present study it was difficult to find patients with persistent ISH and that only a relatively small number of subjects could be randomised.
A method for overcoming transient elevations in BP during clinic measurements is to use 24-h ABPM. In addition, this technique can give information on circadian changes in the BP profile of patients with ISH, especially with an asymmetric dosing regimen. In the present study several patients refused a second ambulatory BP recording. Therefore, the number of patients was too small to detect any statistically significant difference between the ISDN group and placebo with respect to ambulatory BP data. There was a pattern of a rise in SBP in the morning with a decrease at night, comparable to that known in normotensive populations. Other studies have shown that the diurnal BP profile in older patients with ISH is similar to that of other hypertensive patients. 25 The main determinants of the diurnal BP variation in the ISH population were gender, age, smoking habits and the level of pressure on conventional measurements. Office and ambulatory systolic and diastolic BPs decreased and tended to decrease, respectively, during the placebo period in the present study. This was not seen in the SYST-EUR study. 26 However, in the latter study the placebo run-in period lasted 3 months. Therefore, in SYST-EUR a comparison was made between 3 and 4 months of placebo treatment, while in the present study the comparison was done between 6 weeks and 14 weeks. SYST-EUR did not provide data for the 3-month run-in period. Consequently, it is difficult to compare SYST-EUR with the present study.
In the present study the decrease in 24-h mean ambulatory pulse pressure and SBP tended to be more pronounced with ISDN as compared to placebo. This is in line with the office measurements. However, this trend was not present for pulse pressure and systolic pressure at night. The significance of an additional decrease in BP at night in combination with its spontaneous decrease is unknown.
Several studies have shown that all ISH patients are at increased risk for stroke, 48 cardiovascular events 27 and cardiovascular end-organ damage such as left ventricular hypertrophy and increased left ventricular wall stress. 19, 28, 29 Therefore, anti-hypertensive therapy has been proposed for patients with persistent ISH. Most experience with treatment of ISH involves diuretics. 3 The SHEP study (Systolic Hypertension in the Elderly Program) was the first study that demonstrated the efficacy of anti-hypertensive medication in ISH patients. 7, 8 In this study treatment with the diuretic chlorthalidone showed a significant reduction in stroke incidence (36%) and coronary heart disease (27%) over 5 years. Recently, the SYST-EUR study has also shown a significant reduction in stroke (42%) and a decrease in cardiovascular morbidity and mortality (31%). These effects were shown for monotherapy with a calcium antagonist (nitrendipine) and increased after the addition of an angiotensin-converting enzyme (ACE) inhibitor and a diuretic. 4 These data provide evidence that the newer anti-hypertensive agents also improve prognosis in ISH. At the moment the SHELL trial 30 is investigating the effect of long-term treatment with another calcium antagonist (lacidipine), compared to diuretics, on the incidence of cardiovascular mortality and morbidity over a 5-year period in ISH patients.
The most important finding of the present study was a significant decrease in pulse pressure after ISDN treatment when compared to placebo. Duchier et al 21 have shown that treatment of ISH patients with oral sustained-release ISDN also significantly decreased SBP without a decrease in DBP. These effects were sustained after 8 and 12 h of drug intake. The patients in this study were over 80 years of age, while they were 60-80 years in the current study.
The decrease in pulse pressure in the present study is probably achieved by an improvement in arterial compliance 31 which, in turn, is mainly caused by vasodilation in large arteries. Previously, it has been shown that large arteries (carotid artery, femoral artery, aorta) dilate in response to nitrates. 31, 32 As stated before, the haemodynamic characteristics of ISH are primarily attributed to a reduction in arterial compliance rather than to an increase in arterial resistance. 28, 33 The integration of cardiovascular reflexes has been found to be disturbed in patients with ISH. This also might be due to a decrease in arterial compliance. 34 In any case, elevated systolic pressure can be lowered specifically by an active increase in arterial compliance and by reducing pulse wave velocity or reducing wave reflection. 12, 14, 35 Nitrates may actively increase arterial compliance by a reduction in the vascular smooth muscle tone of large arteries. In comparison to other vasoactive drugs, nitrates are additionally capable of a reduction in reflected pressure waves 10, 14, 15, 36 and therefore could offer further advantages in the treatment of ISH.
As well as a decrease in pulse pressure, the present study showed a decrease in SBP, while DBP tended to increase, thus preserving coronary perfusion. Overall, the haemodynamic effects due to treatment with nitrates will decrease cardiac afterload and may lower the risk for stroke, while the risk of decreased coronary perfusion is ruled out.
In conclusion, the present study showed that in elderly patients with ISH pulse pressure decreased with ISDN, resulting in a lower SBP without a decrease in DBP. This lack of decrease in DBP may preserve coronary perfusion in patients with ISH. With the asymmetric dosage regimen, the decrease in pulse pressure was not evident at night. Whether a decrease in BP at night, in addition to the spontaneous decrease, is advisable in patients with ISH remains to be determined.
